AstraZeneca stopped its Phase 3 trial of volrustomig in lung cancer after an independent data monitoring committee review found the bispecific did not show enough efficacy versus the existing standard comparator, Keytruda (pembrolizumab), based on interim results. The decision marks another setback for the company’s late-stage respiratory oncology pipeline.